Targeting stroma and tumor, silencing galectin 1 treats orthotopic mouse hepatocellular carcinoma.
Carbohydrate-binding lectin
Extracellular matrix
Galectin 1
Hepatocellular carcinoma
Liver
Spatial transcriptomics
Translation
Tumor-margin
Journal
Acta pharmaceutica Sinica. B
ISSN: 2211-3835
Titre abrégé: Acta Pharm Sin B
Pays: Netherlands
ID NLM: 101600560
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
received:
28
04
2023
revised:
28
07
2023
accepted:
15
09
2023
medline:
23
1
2024
pubmed:
23
1
2024
entrez:
23
1
2024
Statut:
ppublish
Résumé
This study examines inhibiting galectin 1 (Gal1) as a treatment option for hepatocellular carcinoma (HCC). Gal1 has immunosuppressive and cancer-promoting roles. Our data showed that Gal1 was highly expressed in human and mouse HCC. The levels of Gal1 positively correlated with the stages of human HCC and negatively with survival. The roles of Gal1 in HCC were studied using overexpression (OE) or silencing using
Identifiants
pubmed: 38261802
doi: 10.1016/j.apsb.2023.10.010
pii: S2211-3835(23)00404-5
pmc: PMC10793093
doi:
Types de publication
Journal Article
Langues
eng
Pagination
292-303Informations de copyright
© 2024 The Authors.
Déclaration de conflit d'intérêts
The authors declare no potential competing interests.